Evoke Pharma Enters Agreement with Rho CRO to Submit NDA
Evoke Pharma, Inc.-a pharma company focused on treatments for gastrointestinal diseases-announced an agreement with Rho, Inc.-a regulatory consulting and contract research organization (CRO).
Rho and Evoke will collaborate with the preparation and submission of Evoke's planned 505(b)(2) New Drug Application (NDA) for Gimoti™-the company’s nasal delivery formulation of metoclopramide, which helps relieve symptoms associated with acute and recurrent diabetic gastroparesis in adult women.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025